10 Must-See Presentations from the 2024 SGO Annual Meeting

The 2024 Society for Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer took place in San Diego, California, from March 16 to 18, 2024, where experts in the field of gynecologic oncology met to learn and share results of the latest research.

The latest findings across ovarian, cervical, and endometrial cancers took center stage, including compelling data from the phase 3 KEYNOTE-868 trial (NCT03914612) investigating pembrolizumab (Keytruda) plus chemotherapy in endometrial cancer.

One of the most exciting presentations came from the phase 3 RUBY trial (NCT03981796), where “unprecedented” survival for patients with endometrial cancer was observed with the combination of dostarlimab-gxly (Jemperli) plus chemotherapy.

Treatment of perivascular epithelioid sarcoma (PEComa) with nab-Sirolimus (Fyarro; ABI-009) also was anticipated as the topic of multiple presentations at the meeting.

Here is a look back at the SGO Annual Meeting:

Identifying a Link Between Cervical Cancer and Social Determinants of Health

Social determinants of health—poverty, race, ethnicity, and treatment access—play a critical role in occurrence rates cervical cancer across the United States.

Pembro Combo Betters Survival in Endometrial Cancer

The combination of pembrolizumab plus chemotherapy conferred a positive overall survival (OS) outcome for patients with endometrial cancer, according to findings from the phase 3 NRG-GY018/KEYNOTE-868 trial.

Unprecedented Benefit With Dostarlimab/Chemo in Endometrial Cancer

Dostarlimab and carboplatin/paclitaxel chemotherapy delivered a 31% improvement in OS vs placebo/chemotherapy in patients with primary advanced or recurrent endometrial cancer, regardless of microsatellite instability (MSI) status, according to findings from a second interim analysis of part 1 of the ENGOT-EN6-NSGO/GOG-3031/RUBY trial.

Olaparib/Cediranib Combo Misses the Mark in Ovarian Cancer

Olaparib (Lynparza) plus cediranib did not appear to deliver a statistically significant improvement in progression-free survival (PFS) and OS vs standard-of-care chemotherapy among patients with platinum-resistant or -refractory epithelial ovarian cancer.

PROs Strengthen Case for Mirvetuximab Soravtansine as SOC in FRα+ Ovarian Cancer

Patient-reported outcomes (PROs) from the phase 3 MIRASOL trial (NCT04209855) showed that patients with folate receptor-alpha positive, platinum-resistant ovarian cancer treated with mirvetuximab soravtansine (Elahere) had a better health-related quality of life compared with the investigator’s choice of chemotherapy.

Tislelizumab Plus Chemotherapy Shows Encouraging Responses, Antitumor Activity in Locally Advanced Cervical Cancer

In locally advanced cervical cancer, the combination of neoadjuvant tislelizumab (Tevimbra) plus chemotherapy was shown to be safe with encouraging antitumor activity based on a pathologic complete response in 60.9% and an optimal pathologic response in 73.9% of patients.

Study Investigates Nab-Sirolimus Plus Letrozole in Advanced Endometrial Cancer

A phase 2 study (NCT05997017) investigating the combination of nab-Sirolimus plus letrozole (Femara) in patients with advanced or recurrent endometrial cancer began enrollment in December 2023.

Nab-Sirolimus Delivers Durable Responses in PEComa Subgroups

Nab-Sirolimus delivered rapid and durable responses in patients with PEComa, according to a subgroup analysis of the phase 2 AMPECT study (NCT02494570).

In Endometrial Cancer Treament, Racial Disparities Persist

Disparities in clinical characteristics and outcomes were noted between Black and White women with endometrioid endometrial cancer, particularly with Black patients experiencing an increased risk of death, according to findings from a retrospective study of patients in real-world registries and GOG/NRG randomized phase 3 trials.

ChatGPT Offers New Outlook on Genetic Counseling for Gynecologic Cancers

Using ChatGPT as a tool to pose genetic counseling questions delivered accurate responses for patients with gynecologic cancers.